301. Selective Capture of Anti-N-glucosylated NTHi Adhesin Peptide Antibodies by a Multivalent Dextran Conjugate.
- Author
-
Mazzoleni A, Real-Fernandez F, Nuti F, Lanzillo R, Brescia Morra V, Dambruoso P, Bertoldo M, Rovero P, Mallet JM, and Papini AM
- Subjects
- Anti-Bacterial Agents chemistry, Autoantibodies chemistry, Dextrans chemistry, Glycosylation, Humans, Microbial Sensitivity Tests, Molecular Structure, Peptides chemistry, Adhesins, Bacterial drug effects, Anti-Bacterial Agents pharmacology, Autoantibodies pharmacology, Dextrans pharmacology, Haemophilus influenzae drug effects, Peptides pharmacology
- Abstract
Tentacle-like polymers decorated with several copies of peptide antigens can be interesting tools for increasing the ability to capture circulating antibodies in patient sera, using cooperative effects for stronger avidity. We previously showed that antibodies from multiple sclerosis (MS) patient sera preferentially recognize hyperglucosylated adhesin protein HMW1ct of non-typeable Haemophilus influenzae (NTHi). We selected the C-terminal HMW1ct(1347-1354) minimal epitope and prepared the diglucosylated analogue Ac-KAN(Glc)VTLN(Glc)TTG-K(N
3 )-NH2 to graft a 40 kDa dextran scaffold modified with glycidyl-propargyl moieties to perform a copper catalyzed alkyne-azide coupling reaction (CuAAC). Quantitative NMR measurements allowed the characterization of the peptide loading (19.5 %) on the multivalent dextran conjugate. This novel polymeric structure displayed optimal capturing properties of both IgG and, more interestingly, IgM antibodies in MS sera. Specific antibodies from a representative MS serum, were successfully depleted using a Sepharose resin bearing the new glucosylated multivalent conjugate, as confirmed by ELISA. These results may offer a promising proof-of-concept for the selective purification of high affinity autoantibodies from sera of autoimmune patients, in general, and of specific high affinity antibodies against a minimally glcosylated epitope Asn(Glc) from sera of multiple sclerosis (MS) patients, in particular., (© 2021 The Authors. ChemBioChem published by Wiley-VCH GmbH.)- Published
- 2022
- Full Text
- View/download PDF